Breast Cancer Anti-Estrogen Resistance Protein 1 (Bcar1) Antibody
292.5€ (80 µl)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Breast Cancer Anti-Estrogen Resistance Protein 1 (Bcar1) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx034763
tested applications
ELISA, WB
Description
Docking protein which plays a central coordinating role for tyrosine kinase-based signaling related to cell adhesion. Implicated in induction of cell migration (By similarity). Has been shown to be essential in cardiovascular development during embryogenesis.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Breast Cancer Anti-Estrogen Resistance Protein 1 (Bcar1) |
| Host | Rabbit |
| Reactivity | Mouse |
| Recommended Dilution | WB: 1/1000. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Polyclonal |
| Conjugation | Unconjugated |
| Isotype | IgG |
| Purification | Purified through a protein A column, followed by peptide affinity purification. |
| Size 1 | 80 µl |
| Size 2 | 400 µl |
| Form | Liquid |
| Tested Applications | ELISA, WB |
| Buffer | PBS containing 0.09% sodium azide. |
| Availability | Shipped within 5-10 working days. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | Q61140 |
| Alias | BCAR1, CAS, CAS1, CASS1, CRKAS, P130Cas, Cas family scaffolding protein, Cas family scaffold protein, BCAR1 scaffold protein, Cas family member |
| Background | Antibody anti-BCAR1 |
| Status | RUO |
Descripción
BCAR1, also known as the Breast Cancer Anti-Estrogen Resistance 1 protein, is an important protein involved in the development of resistance to anti-estrogen therapies, such as tamoxifen, used in the treatment of estrogen receptor-positive breast cancer. BCAR1 plays a crucial role in cell signaling pathways that regulate cell survival, proliferation, and resistance to apoptosis. It is often upregulated in breast cancer cells that become resistant to estrogen receptor-targeted therapies. The protein interacts with several other signaling molecules involved in the regulation of cell motility and survival, contributing to the metastatic potential of breast cancer cells. Understanding BCAR1’s role in therapy resistance has significant implications for developing alternative therapeutic strategies for patients with estrogen receptor-positive breast cancer who develop resistance to current treatments.
Related Products
Human BCAR1(Breast Cancer Anti Estrogen Resistance 1) ELISA Kit
Ver Producto
anti- BCAR1 antibody
Ver Producto